K. Gordon, “BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients”, J of Skin, vol. 4, no. 5, p. s28, Sep. 2020.